Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited (IMMP) news covers a late-stage biotechnology company focused on Lymphocyte Activation Gene-3 (LAG-3)–related immunotherapies for cancer and autoimmune disease. The company regularly reports clinical, regulatory and corporate developments across its diversified LAG-3 portfolio, led by the MHC Class II agonist eftilagimod alfa (efti) and the LAG-3 agonist antibody IMP761.
On this page, readers can follow updates on Immutep’s major oncology programs, including the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, as well as Phase II and investigator-initiated studies in head and neck squamous cell carcinoma, soft tissue sarcoma and metastatic breast cancer. News items highlight trial milestones such as patient enrolment progress, primary endpoint readouts, translational biomarker data and presentations at international conferences like the European Society for Medical Oncology (ESMO), the World Conference on Lung Cancer and the San Antonio Breast Cancer Symposium.
For autoimmune disease, Immutep publishes updates on the Phase I program for IMP761, a first-in-class LAG-3 agonist antibody designed to silence dysregulated self-antigen-specific memory T cells. News coverage includes safety, pharmacodynamic findings and proof-of-concept data from the ongoing first-in-human study.
Investors can also track regulatory interactions, such as Fast Track designations, FDA feedback on late-stage development strategies and completion of Project Optimus requirements, alongside business developments like the strategic collaboration and exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected global markets. Corporate news, including R&D tax incentives from French and Australian government programs and quarterly activity reports, provides additional context on funding and operational progress.
Bookmark this page to monitor Immutep’s latest announcements, clinical data disclosures and SEC Form 6-K filings that shape the outlook for IMMP and its LAG-3–focused pipeline.
Immutep (ASX: IMM; NASDAQ: IMMP) will present new data from its phase II TACTI-002 trial at the European Lung Cancer Congress (ELCC) 2022 in Prague and virtually from March 30 to April 2, 2022. The study evaluates eftilagimod alpha combined with KEYTRUDA® in patients with PD-L1 unselected, refractory metastatic non-small cell lung cancer (NSCLC). The poster presentation is scheduled for April 1, 2022, at 12:00 noon CEST by Dr. Matthew G. Krebs. Immutep aims to advance its LAG-3 related immunotherapeutic developments.
Immutep Limited (NASDAQ: IMMP) announced the grant of a new patent by the Australian Patent Office for its lead immunotherapy candidate, eftilagimod alpha (efti or IMP321). This patent, protecting combined preparations for treating cancer, follows similar grants in Europe, the U.S., and China. The claims cover specific combinations of efti with various anti-PD-1/PD-L1 antibodies, expiring on January 8, 2036. CEO Marc Voigt highlighted the importance of this patent in the context of significant interest in the LAG-3 mechanism following Phase III clinical data publication.
Immutep (ASX: IMM; NASDAQ: IMMP) has announced participation in two key investor conferences in February 2022. CEO Marc Voigt will present at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, followed by a Q&A session on February 18 at 3:40 PM ET. Additionally, Immutep will be at the 2022 BIO CEO & Investor Conference from February 14-17. The company's focus is on developing immunotherapy treatments for cancer and autoimmune diseases, primarily through its lead candidate, eftilagimod alpha.
Immutep Limited (NASDAQ: IMMP) reported significant advancements in its clinical trials for cancer therapies, particularly its lead product, eftilagimod alpha (efti). The Phase IIb AIPAC trial demonstrated a notable overall survival benefit, with a +7.5 month increase for patients under 65 and +19.6 months for those with low monocytes. The company is preparing for a Phase III trial and has initiated patient recruitment for TACTI-003. Financially, cash on hand is $99.66 million, projected to fund operations until December 2023.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a Manufacturing Service Agreement with Northway Biotech to produce its preclinical candidate, IMP761, aimed at autoimmune diseases. Northway will develop a GMP-compliant manufacturing process for IMP761 at its facility in Lithuania, with plans for clinical trials post-preclinical development. IMP761 targets autoimmune memory T cells expressing LAG-3, potentially addressing the root causes of autoimmune diseases. Preclinical results from 2019 indicated its ability to reduce T cell infiltration.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the treatment of the first five patients in its INSIGHT-003 study, which evaluates a triple combination therapy featuring eftilagimod alpha (efti) alongside chemotherapy and anti-PD-1 therapy. The study, led by Prof. Dr. Salah-Eddin Al-Batran, has reported no new safety signals and is progressing well, with patient recruitment on track. Up to 20 patients with solid tumors will be recruited, assessing safety, tolerability, and initial efficacy, with further results anticipated in 2022.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the successful completion of patient recruitment for the Phase II TACTI-002 study, targeting non-small cell lung cancer (NSCLC) and head & neck squamous cell carcinoma (HNSCC). With 185 patients enrolled across all study parts, recruitment was completed under 12 months, surpassing expectations. Interim data from Part C was presented at the SITC Annual Meeting 2021, with further results anticipated in early 2022. This milestone reflects Immutep's commitment to advancing immunotherapy research in challenging pandemic conditions.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of a new patent from the Chinese Patent Office for its immunotherapy candidate, eftilagimod alpha (efti or IMP321). The patent protects combined therapeutic preparations involving efti and anti-PD-1 or anti-PD-L1 antibodies, expiring on January 8, 2036. This follows similar patents granted in Europe and the U.S. between 2018 and 2021. The patent is exclusively licensed to EOC Pharma, which will pay milestone payments and royalties as efti progresses through trials in China.
Immutep Limited (NASDAQ: IMMP) presented promising data at the SITC Annual Meeting 2021, highlighting significant Overall Survival (OS) improvements in patient subgroups from its AIPAC trial. Key findings indicate a median OS of 22.3 months for patients under 65 and 32.5 months for those with low monocyte counts. The Phase II TACTI-002 study revealed a 29.7% Overall Response Rate (ORR) in second-line head and neck cancer patients. The company’s candidate, efti, continues to show potential for improving quality of life and long-term outcomes in cancer treatment.
Immutep Limited has reported promising results from the TACTI-002 trial, noting an Objective Response Rate (ORR) of 29.7% in patients with second-line head and neck squamous cell carcinoma (HNSCC). This study included 37 patients, with 5 achieving complete responses. Additionally, Immutep will recruit 154 first-line HNSCC patients for the TACTI-003 study to assess ORR as the primary endpoint. Detailed data from the AIPAC trial will be presented in an investor webcast on November 17, 2021.